Here is an overview of the seven drugs analyzed by the institute. The costs to the U.S. healthcare system were calculated after factoring in drug company rebates and other rebates.
- The price of Humira, which treats severe Crohn’s disease, was up 9.6 percent. Cost in the United States: $ 1.4 billion.
- The price of Promacta, which treats a blood disorder called chronic immune thrombocytopenic purpura (ITP), increased by 14.1%. Cost in the United States: $ 100 million.
- The price of Tysabri, a monoclonal antibody used to treat multiple sclerosis, increased 4.2 percent. Cost in the United States: $ 44 million.
- The price of Xifaxan, used to treat irritable bowel syndrome, increased 3 percent. Cost in the United States: $ 44 million.
- The price of Troken di, used to prevent migraines, increased 12.4 percent. Cost in the United States: $ 36 million.
- The price of Lupron deposit, used to treat endometriosis in women and prostate cancer in men, increased 5.9 percent. Cost in the United States: $ 30 million.
- The price of Krystexxa, used to treat chronic gout, increased 5.2 percent. Cost in the United States: $ 19 million.
AARP continues its fight for lower drug prices
The report’s findings are consistent with the AARP Price Watch reports which show that price increases for brand name drugs continue to outpace inflation. The latest AARP report found that in 2020 the prices of 260 commonly used drugs whose AARP prices have tracked since 2006 rose 2.9% while the overall inflation rate was 1.3% .
AARP’s Fair Rx Prices Now campaign aimed to convince federal and state lawmakers to take action to lower prescription drug prices.
On November 19, the US House of Representatives passed a law that would bring some financial relief to patients. Under the AARP-backed Build Back Better Act, Medicare could for the first time negotiate the price of certain drugs, the cost of certain insulin would be capped at $ 35 per month, drug manufacturers would be subject to tax penalties. ‘they were raising prices. more than inflation, and reimbursable costs for Part D prescription drugs would be capped at $ 2,000 per year. The bill now goes to the United States Senate.
Dena Bunis covers Medicare, Health Care, Health Policy, and Congress. She also writes the column “Medicare Made Easy” for the AARP Bulletin. Award-winning journalist Bunis has spent decades working for metropolitan dailies, most notably as Washington bureau chief for the Orange County Register and as a health and workplace policy writer for Press day.